Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 2016

View Archived Issues

Emulate enters translational R&D collaboration

Roche reviews highlights of third quarter 2016

TxCell and UBC begin strategic collaboration to develop CAR-Tregs in solid organ transplantation

BlackThorn Therapeutics closes series A financing

Merck & Co. patents BTK inhibitors

Rigel Pharmaceuticals discloses TGF-beta and/or GDF-8 inhibitors

MedImmune begins phase I study of anti-ILT-7 antibody

AbbVie describes TRPV3 receptor antagonists

FDA approves Zinplava to reduce recurrence of C. difficile infection

FDA approves updated labeling for Xtandi

Gilead Sciences reports results of three phase II studies of selonsertib

Merck & Co.'s KEYNOTE-045 study meets primary endpoint

Daiichi Sankyo updates decision on phase III study of pexidartinib in tenosynovial giant cell tumor

Bristol-Myers Squibb develops IDO inhibitors

Phase II results on OMS-721 in stem cell transplant-associated thrombotic microangiopathy

Daiichi Sankyo reports Japanese phase III results for prasugrel in ischemic cerebrovascular disease

Gilead Sciences provides results from phase III studies of sofosbuvir/velpatasvir/voxilaprevir

Phase III efficacy trials of revefenacin in COPD meet primary endpoint

NeuroVive and Arbutus terminate NVP-018 agreement

FDA committee votes in favor of approving SER-120 for nocturia

FDA accepts resubmitted NDA for safinamide

Phase III study of denosumab in MM meets primary enpoint

VBI-1901 shows promising preclinical results

GSK submits BLA for Shingrix

Janssen presents phase I results for ExPEC4v

Multiplatform imaging of systemic amyloidosis with the new peptide p5+14

New mutations in known disease-associated genes

Discovery of new biomarkers for conditions

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...